IU Licenses Breast Cancer Biomarker to Clarient | GenomeWeb

NEW YORK (GenomeWeb News) – Indiana University has licensed a breast cancer biomarker that researchers at the school have discovered to Clarient for development as a pharmacogenomic assay, the school said today.

According to IU, patients who test positive for the biomarker — FOXA1 — are more likely to respond to anti-estrogen hormone therapies, such as tamoxifen. The university said that in two studies involving around 675 patients, those who tested positive for the presence of FOXA1 had cancer considered less aggressive.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PLOS this week: nasal microbial communities in asthma patients; sequencing-based way to detect, track schistosomiasis; and more.

The New York Times speaks with Vanderbilt's John Anthony Capra about Neanderthal genes in modern humans.

A draft guidance from the FDA suggests the agency wants to more tightly control gene-edited animals, according to Technology Review.

Researchers were among this weekend's protesters bemoaning the new US administration, Vox reports.